KR102655779B1 - 콘드로이틴 황산 유도체 및 방광 질환 처치제 - Google Patents
콘드로이틴 황산 유도체 및 방광 질환 처치제 Download PDFInfo
- Publication number
- KR102655779B1 KR102655779B1 KR1020237009204A KR20237009204A KR102655779B1 KR 102655779 B1 KR102655779 B1 KR 102655779B1 KR 1020237009204 A KR1020237009204 A KR 1020237009204A KR 20237009204 A KR20237009204 A KR 20237009204A KR 102655779 B1 KR102655779 B1 KR 102655779B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- steroid
- spacer
- bladder
- chondroitin sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015003572 | 2015-01-09 | ||
| JPJP-P-2015-003572 | 2015-01-09 | ||
| KR1020177021920A KR102512431B1 (ko) | 2015-01-09 | 2016-01-08 | 콘드로이틴 황산 유도체 및 방광 질환 처치제 |
| PCT/JP2016/050526 WO2016111356A1 (ja) | 2015-01-09 | 2016-01-08 | コンドロイチン硫酸誘導体及び膀胱疾患処置剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177021920A Division KR102512431B1 (ko) | 2015-01-09 | 2016-01-08 | 콘드로이틴 황산 유도체 및 방광 질환 처치제 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230047193A KR20230047193A (ko) | 2023-04-06 |
| KR102655779B1 true KR102655779B1 (ko) | 2024-04-05 |
Family
ID=56356041
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237009204A Active KR102655779B1 (ko) | 2015-01-09 | 2016-01-08 | 콘드로이틴 황산 유도체 및 방광 질환 처치제 |
| KR1020177021920A Active KR102512431B1 (ko) | 2015-01-09 | 2016-01-08 | 콘드로이틴 황산 유도체 및 방광 질환 처치제 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177021920A Active KR102512431B1 (ko) | 2015-01-09 | 2016-01-08 | 콘드로이틴 황산 유도체 및 방광 질환 처치제 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10350236B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3757136B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6026708B1 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102655779B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107108761B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2972866C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2828692T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016111356A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10350236B2 (en) * | 2015-01-09 | 2019-07-16 | Seikagaku Corporation | Chondroitin sulfate derivative and agent for treating bladder diseases |
| JP7660066B2 (ja) * | 2019-10-03 | 2025-04-10 | 生化学工業株式会社 | 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム |
| RU2751649C1 (ru) * | 2020-08-24 | 2021-07-15 | Наталья Геннадиевна Галкина | Способ лечения и профилактики цистита |
| AU2022348759A1 (en) * | 2021-09-16 | 2024-01-25 | Coval Biopharma (Shanghai) Co., Ltd. | Drug delivery system for locally delivering therapeutic agents and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006517928A (ja) * | 2003-02-19 | 2006-08-03 | ステラー・インターナシヨナル・インコーポレーテツド | 高用量のコンドロイチン硫酸を用いた膀胱炎の処置 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2604930B2 (ja) * | 1990-12-14 | 1997-04-30 | 株式会社ディ・ディ・エス研究所 | ヒアルロン酸およびコンドロイチン誘導体 |
| US6562781B1 (en) * | 1995-11-30 | 2003-05-13 | Hamilton Civic Hospitals Research Development Inc. | Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
| US6083933A (en) | 1999-04-19 | 2000-07-04 | Stellar International Inc. | Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution |
| ITPD20020271A1 (it) * | 2002-10-18 | 2004-04-19 | Fidia Farmaceutici | Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati. |
| CN101921347B (zh) * | 2004-01-07 | 2014-07-30 | 生化学工业株式会社 | 透明质酸衍生物及含有其的药剂 |
| KR20080065269A (ko) * | 2005-08-03 | 2008-07-11 | 모리아 바이오파마슈티컬스 | 낭포성 섬유증에 대한 리피드 접합체의 용도 및 그의 적용 |
| IE20070900A1 (en) * | 2007-12-12 | 2009-06-24 | Eurand Pharmaceuticals Ltd | New anticancer conjugates |
| JP2015003572A (ja) | 2013-06-20 | 2015-01-08 | トヨタ紡織株式会社 | 乗物用シート |
| WO2015005459A1 (ja) * | 2013-07-10 | 2015-01-15 | 生化学工業株式会社 | 呼吸器投与用の医薬組成物 |
| US10098962B2 (en) | 2013-07-10 | 2018-10-16 | Seikagaku Corporation | Glycosaminoglycan derivative and method for producing same |
| US10350236B2 (en) * | 2015-01-09 | 2019-07-16 | Seikagaku Corporation | Chondroitin sulfate derivative and agent for treating bladder diseases |
-
2016
- 2016-01-08 US US15/542,226 patent/US10350236B2/en active Active
- 2016-01-08 CN CN201680005171.0A patent/CN107108761B/zh active Active
- 2016-01-08 KR KR1020237009204A patent/KR102655779B1/ko active Active
- 2016-01-08 WO PCT/JP2016/050526 patent/WO2016111356A1/ja not_active Ceased
- 2016-01-08 EP EP20191098.1A patent/EP3757136B1/en active Active
- 2016-01-08 JP JP2016517573A patent/JP6026708B1/ja active Active
- 2016-01-08 EP EP16735095.8A patent/EP3243841B1/en active Active
- 2016-01-08 KR KR1020177021920A patent/KR102512431B1/ko active Active
- 2016-01-08 ES ES16735095T patent/ES2828692T3/es active Active
- 2016-01-08 CA CA2972866A patent/CA2972866C/en active Active
- 2016-10-12 JP JP2016200801A patent/JP6748551B2/ja active Active
-
2019
- 2019-05-31 US US16/427,875 patent/US10953037B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006517928A (ja) * | 2003-02-19 | 2006-08-03 | ステラー・インターナシヨナル・インコーポレーテツド | 高用量のコンドロイチン硫酸を用いた膀胱炎の処置 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3243841A4 (en) | 2018-07-11 |
| KR20230047193A (ko) | 2023-04-06 |
| JP2017036455A (ja) | 2017-02-16 |
| US10350236B2 (en) | 2019-07-16 |
| EP3757136B1 (en) | 2023-07-19 |
| CN107108761A (zh) | 2017-08-29 |
| JPWO2016111356A1 (ja) | 2017-04-27 |
| WO2016111356A1 (ja) | 2016-07-14 |
| US10953037B2 (en) | 2021-03-23 |
| KR20170098942A (ko) | 2017-08-30 |
| CA2972866A1 (en) | 2016-07-14 |
| JP6748551B2 (ja) | 2020-09-02 |
| ES2828692T3 (es) | 2021-05-27 |
| US20170354675A1 (en) | 2017-12-14 |
| EP3757136A1 (en) | 2020-12-30 |
| KR102512431B1 (ko) | 2023-03-22 |
| EP3243841A1 (en) | 2017-11-15 |
| CN107108761B (zh) | 2020-06-30 |
| JP6026708B1 (ja) | 2016-11-16 |
| CA2972866C (en) | 2023-08-22 |
| US20190282607A1 (en) | 2019-09-19 |
| EP3243841B1 (en) | 2020-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2741439T3 (es) | Compuestos aromáticos sustituidos | |
| US20260014072A1 (en) | Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose | |
| US10953037B2 (en) | Chondroitin sulfate derivative and agent for treating bladder diseases | |
| JP2005533810A (ja) | 新規な抗コレステロール組成物及びその使用方法 | |
| AU2017321782A1 (en) | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases | |
| TWI564291B (zh) | 一氧化氮生成調節劑 | |
| AU2018201544B2 (en) | Tocopherol and tocopheryl quinone derivatives as correctors of Lysosomal Storage Disorders | |
| JP2025094276A (ja) | 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム、医薬組成物、及び膀胱疾患処置剤 | |
| HK40039515A (en) | Chondroitin sulfate derivative and agent for treating bladder diseases | |
| MXPA99003616A (en) | Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics | |
| HK1217300B (en) | Treatment of oculopharyngeal muscular dystrophy by intravenous administration of trehalose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20230316 Application number text: 1020177021920 Filing date: 20170804 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230712 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240110 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240403 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240403 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |